Skip to main content

Table 5 Neutropaenia day 0 severity grade compared to maximum severity grade at follow up, safety population

From: Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia

Study-T   ASAQ AL
(>5 years)   N = 482* N = 490*
Neutropenia grade at day 0 Maximum Neutropenia grade after day 0 Patients N (%)
0 0 332 (68.9) 325 (66.3)
1 0 33 (6.8) 25 (5.1)
2 0 2 (0.4) 2 (0.4)
missing 0 3 (0.6) 3 (0.6)
0 1 59 (12.2) 73 (14.9)
1 1 28 (5.8) 31 (6.3)
2 1 3 (0.6) 7 (1.4)
3 1 0 (0.0) 2 (0.4)
missing 1 4 (0.8) 3 (0.6)
0 2 6 (1.2) 7 (1.4)
1 2 6 (1.2) 5 (1.0)
2 2 6 (1.2) 2 (0.4)
3 2 0 (0.0) 1 (0.2)
1 3 2 (0.4) 1 (0.2)
3 3 1 (0.2) 0 (0.0)
Any worsening after baseline 73 (15.1) 86 (17.6)
Study-E   ASAQ AL
(6-59 months)   N = 142* N = 143*
Neutropenia grade at day 0 Maximum Neutropenia grade after day 0 Patients N (%)
0 0 121 (85.2) 125 (87.4)
1 0 3 (2.1) 3 (2.1)
missing 0 9 (6.3) 7 (4.9)
0 1 6 (4.2) 6 (4.2)
1 1 3 (2.1) 2 (1.4)
Any worsening after baseline 6 (4.2) 6 (4.2)
  1. * Shift tables were created for all patients with at least one neutrophil count available after day 0.